Еще раз о клинической эффективности и безопасности сартанов
Аннотация
Ключевые слова
Об авторах
Е. С. МининаРоссия
Б. Р. Хаджиева
Россия
Список литературы
1. Conlin P.R, Gerth W.C, Fox J et al. Four - year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clin Ther 2001; 23 (12): 1999-2010.
2. Erkens J.A, Panneman M.M, Klungel O.H et al. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf 2005; 14 (11): 795-803.
3. Van Liefde I, Vauquelin G. Sartan AT1-receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism. Mol Cell Endocrinol 2009; 302 (2): 237-43.
4. Ojima M et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011; 336 (3): 801-8.
5. Elmfeldt D, George M, Hubner R, Olofsson B. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens 1997; (11 Suppl. 2): s49-53.
6. Lindholm L.H, Persson M, Alaupovic P et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21 (8): 1563-74.
7. Asmar R, Nisse-Durgeat S. A large scale study of angiotensin II inhibition therapy in an elderly population: the CHANCE study. Vasc Health Risk Manag 2006; 2 (3): 317-23.
8. Granger C.B, Mc Murray J.J, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin converting enzyme inhibitors: the CHARM. Alternative Trial Lancet 2003; 362: 772-6.
9. Мареев В.Ю., Агеев Ф.Т. и др. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (2-й пересмотр). Сердечная недостаточность. 2006; 8 (2).
10. Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Eldery (SCOPE): principal results of a randomized double - blind intervention trial. J Hypertens 2003; 21: 875-86.
11. Rakugi H et al. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double - blind clinical study. Hypertens Res 2012; 35 (5): 552-8.
12. Инструкция по медицинскому применению препарата Эдарби®. URL: http://grls.rosminzdrav.ru/Grls_View.aspx?idReg= 146017&isOld=0&t
13. Инструкция по медицинскому применению препарата АтакандR. URL: http://grls.rosminzdrav.ru/ImgInstr.aspx?folder= ScanVavilova&Filepath=/Ne_trebuet_vnesenia/Net_ND_IZM/439736/ IP_IZM&idReg=106933&isOld=0&fileType=jpg&pfolder=2
14. Reif M et al. Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators. Am J Cardiol 1998; 82: 961-5.
15. Bonner G, Bakris G, Sica D et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin - converting enzyme inhibitor ramipril. J Hum Hypertens 2013; 27: 479-86.
16. Sica D et al. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. Clin Hypertens (Greenwich) 2011; 13 (7): 467-72.
Рецензия
Для цитирования:
Минина Е.С., Хаджиева Б.Р. Еще раз о клинической эффективности и безопасности сартанов. Системные гипертензии. 2014;11(4):84-86.
For citation:
Minina Ye.S., Khadzhieva B.R. Once again about the clinical efficacy and safety of sartans. Systemic Hypertension. 2014;11(4):84-86.
Послать статью по эл. почте 